成纤维细胞在肝癌发生发展中的作用

doi:10.11904/j.issn.1002-3070.2022.02.012

Abstract

Abstract: Liver fibrosis and further cirrhosis are important factors in the occurrence and development of liver cancer.Fibroblasts can deposit extracellular matrix,and extracellular matrix deposition is also a hallmark of liver fibrosis.Liver fibrosis and further cirrhosis are important factors in the occurrence and development of liver cancer.There are many sources of fibroblasts,and the different sources are mainly due to the different nature of liver damage.It is currently believed that fibroblasts are mainly derived from hepatic stellate cells(Hepatic stellate cells,HSCs),also known as Ito cells.Liver fibroblasts can transform into cancer-associated fibroblasts(CAFs)during the occurrence and development of hepatocellular carcinoma(HCC).The role of activated hepatic stellate cells(activated HSCs,AHSCs)/tumor-associated fibroblasts(CAFs)in the occurrence and development of HCC has been confirmed.CAFs are a group of activated fibroblasts with different cell sources and phenotypes in the tumor microenvironment(TME)of HCC,and are closely related to the occurrence and development of tumors.CAFs may secrete a variety of growth factors and cytokines,promote extracellular matrix remodeling,enhance the stemness of liver cancer cells,promote tumor resistance,promote liver cancer angiogenesis and vasculogenic mimicry(Vm)to affect tumors cell proliferation,apoptosis,migration,invasion,angiogenesis,immune escape and drug resistance.Because of the above characteristics,CAFs can be used as ideal targets in tumor treatment.In this review,we will explain the latest understanding of HCC CAFs,their cell origin and biological functions.

Key words: Cancer-associated fibroblasts, Hepatocellular carcinoma, Tumor microenvironment, Molecular targets

CLC Number:

R730.22

LIU Yu, YU Xingxin, GENG Zhida, CHEN Zhengliang, HUI Peng, LIANG Yingjian. The role of liver fibroblasts in the occurrence and development of hepatocellular carcinoma[J]. Journal of Practical Oncology, 2022, 36(2): 167-172.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.02.012

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I2/167

References

1 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
2 Azar SS,Mansoori M,Attar M,et al.Tumor necrosis factor alpha 308 G/A single nucleotide polymorphism and susceptibility to hepatocellular carcinoma via hepatitis B infection[J].Asian Pac J Cancer Prev,2016,17(7):3381-3384.
3 Medavaram S,Zhang Y.Emerging therapies in advanced hepatocellular carcinoma[J].Exp Hematol Oncol,2018,7:17.
4 Hernandez-Gea V,Friedman SL.Pathogenesis of liver fibrosis[J].Annu Rev Pathol,2011,6:425-456.
5 O′Rourke JM,Sagar VM,Shah T,et al.Carcinogenesis on the background of liver fibrosis:implications for the management of hepatocellular cancer[J].World J Gastroenterol,2018,24(39):4436-4447.
6 Jung YK,Yim HJ.Reversal of liver cirrhosis:current evidence and expectations[J].Korean J Intern Med,2017,32(2):213-228.
7 Buti M,Fung S,Gane E,et al.Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years[J].Hepatol Int,2015.9(2):243-250.
8 D′Ambrosio R,Aghemo A,Rumi MG,et al.A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis[J].Hepatology,2012,56(2):532-543.
9 Papatheodoridis GV,Chan HL,Hansen BE,et al.Risk of hepatocellular carcinoma in chronic hepatitis B:assessment and modification with current antiviral therapy[J].J Hepatol,2015,62(4):956-967.
10 Bang CS,Song IH.Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C:systematic review and meta-analysis[J].BMC Gastroenterol,2017,17(1):46.
11 Kaplan DE.Immunopathogenesis of hepatitis c virus infection[J].Gastroenterol Clin North Am,2015,44(4):735-760.
12 Friedman SL.Mechanisms of hepatic fibrogenesis[J].Gastroenterology,2008,134(6):1655-1669.
13 Tsuchida T,Friedman SL.Mechanisms of hepatic stellate cell activation[J].Nat Rev Gastroenterol Hepatol,2017,14(7):397-411.
14 Affo S,Yu LX,Schwabe RF.The role of cancer-associated fibroblasts and fibrosis in liver cancer[J].Annu Rev Pathol,2017,12:153-186.
15 Kostallari E,Hirsova P,Prasnicka A,et al.Hepatic stellate cell-derived platelet-derived growth factor receptor-alpha-enriched extracellular vesicles promote liver fibrosis in mice through SHP2[J].Hepatology,2018,68(1):333-348.
16 Mederacke I,Hsu CC,Troeger JS,et al.Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology[J].Nat Commun,2013,4:2823.
17 Zhou Y,Ren H,Dai B,et al.Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts[J].J Exp Clin Cancer Res,2018,37(1):324.
18 Zou B,Liu X,Gong Y,et al.A novel 12-marker panel of cancer-associated fibroblasts involved in progression of hepatocellular carcinoma[J].Cancer Manag Res,2018,10:5303-5311.
19 Sekiya S,Miura S,Matsuda-Ito K,et al.Myofibroblasts derived from hepatic progenitor cells create the tumor microenvironment[J].Stem Cell Reports,2016,7(6):1130-1139.
20 Pan T,Chen Y,Zhuang Y,et al.Synergistic modulation of signaling pathways to expand and maintain the bipotency of human hepatoblasts[J].Stem Cell Res Ther,2019,10(1):364.
21 Kollmorgen G,Palme K,Seidl A,et al.A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer[J].Sci Rep,2017,7(1):18086.
22 Li Y,Wang J,Asahina K.Mesothelial cells give rise to hepatic stellate cells and myofibroblasts via mesothelial-mesenchymal transition in liver injury[J].Proc Natl Acad Sci U S A,2013,110(6):2324-2329.
23 Lua I,Asahina K.The role of mesothelial cells in liver development,injury,and regeneration[J].Gut Liver,2016,10(2):166-176.
24 Shafiq A,Suwakulsiri W,Rai A,et al.Transglutaminase-2,RNA-binding proteins and mitochondrial proteins selectively traffic to MDCK cell-derived microvesicles following H-Ras-induced epithelial-mesenchymal transition[J].Proteomics,2021,21(13/14):2000221.
25 Gu X,Huang D,Ci L,et al.Fate tracing of hepatocytes in mouse liver[J].Sci Rep,2017,7(1):16108.
26 Zeisberg M,Yang C,Martino M,et al.Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition[J].J Biol Chem,2007,282(32):23337-23347.
27 Scholten D,Osterreicher CH,Scholten A,et al.Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice[J].Gastroenterology,2010,139(3):987-998.
28 Taura K,Miura K,Iwaisako K,et al.Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice[J].Hepatology,2010,51(3):1027-1036.
29 Xu J,Liu X,Koyama Y,et al.The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies[J].Front Pharmacol,2014,5:167.
30 Nunnari G,Vancheri C,Gilli E,et al.Circulating fibrocytes as a marker of liver fibrosis in chronic hepatitis C[J].Front Biosci(Elite Ed),2010,2:1241-1245.
31 Iwaisako K,Jiang C,Zhang M,et al.Origin of myofibroblasts in the fibrotic liver in mice[J].Proc Natl Acad Sci U S A,2014,111(32):3297-3305.
32 Nishio T,Hu R,Koyama Y,et al.Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice[J].J Hepatol,2019,71(3):573-585.
33 Naba A,Clauser KR,Mani DR,et al.Quantitative proteomic profiling of the extracellular matrix of pancreatic islets during the angiogenic switch and insulinoma progression[J].Sci Rep,2017,7:40495.
34 Ghaly M,Gogineni E,Saif MW.The Evolving field of stereotactic body radiation therapy in pancreatic cancer[J].Pancreas(Fairfax),2019,3(1):9-14.
35 Santamato A,Fransvea E,Dituri F,et al.Hepatic stellate cells stimulate HCC cell migration via laminin-5 production[J].Clin Sci(Lond),2011,121(4):159-168.
36 Fiori ME,Di Franco S,Villanova L,et al.Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance[J].Mol Cancer,2019,18(1):70.
37 Pan X,Li M,Huang L,et al.CD44,IL-33,and ST2 gene polymorphisms on hepatocellular carcinoma susceptibility in the Chinese population[J].Biomed Res Int,2020,2020:2918517.
38 Zhang T,Huang Y,Liu W,et al.Overexpression of zinc finger protein 687 enhances tumorigenic capability and promotes recurrence of hepatocellular carcinoma[J].Oncogenesis,2017,6(7):e363.
39 Lau EY,Lo J,Cheng BY,et al.Cancer-associated fibroblasts regulate tumor-initiating cell plasticity in hepatocellular carcinoma through c-Met/FRA1/HEY1 signaling[J].Cell Rep,2016,15(6):1175-1189.
40 Li Y,Wang R,Xiong S,et al.Cancer-associated fibroblasts promote the stemness of CD24+ liver cells via paracrine signaling[J].J Mol Med(Berl),2019,97(2):243-255.
41 Xiong S,Wang R,Chen Q,et al.Cancer-associated fibroblasts promote stem cell-like properties of hepatocellular carcinoma cells through IL-6/STAT3/Notch signaling[J].Am J Cancer Res,2018,8(2):302-316.
42 Xu J,Wan Z,Tang M,et al.N6-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling[J].Mol Cancer,2020,19(1):163.
43 Fang T,Lv H,Lv G,et al.Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer[J].Nat Commun,2018.9(1):191.
44 Peng H,Xue R,Ju Z,et al.Cancer-associated fibroblasts enhance the chemoresistance of CD73+ hepatocellular carcinoma cancer cells via HGF-Met-ERK1/2 pathway[J].Ann Transl Med,2020,8(14):856.
45 Liu J,Li P,Wang L,et al.Cancer-associated fibroblasts provide a stromal niche for liver cancer organoids that confers trophic effects and therapy resistance[J].Cell Mol Gastroenterol Hepatol,2021,11(2):407-431.
46 Bai C,Sun Y,Pan X,et al.Antitumor effects of trimethylellagic acid isolated from sanguisorba officinalis L.on colorectal cancer via angiogenesis inhibition and apoptosis induction[J].Front Pharmacol,2019,10:1646.
47 Hanahan D,Weinberg RA.Hallmarks of cancer:the next generation[J].Cell,2011,144(5):646-674.
48 Kubo N,Araki K,Kuwano H,et al.Cancer-associated fibroblasts in hepatocellular carcinoma[J].World J Gastroenterol,2016,22(30):6841-6850.
49 Xia Y,Cai XY,Fan JQ,et al.The role of sema4D in vasculogenic mimicry formation in non-small cell lung cancer and the underlying mechanisms[J].Int J Cancer,2019,144(9):2227-2238.
50 Louault K,Li RR,DeClerck YA.Cancer-associated fibroblasts:understanding their heterogeneity[J].Cancers(Basel),2020,12(11):3108.
51 Monteran L,Erez N.The dark side of fibroblasts:cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment[J].Front Immunol,2019,10:1835.
52 Law AM,Lim E,Ormandy CJ,et al.The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy[J].Endocr Relat Cancer,2017,24(4):123-144.
53 Li J,Sun J,Rong R,et al.HMGB1 promotes myeloid-derived suppressor cells and renal cell carcinoma immune escape[J].Oncotarget,2017,8(38):63290-63298.
54 Cheng JT,Deng YN,Yi HM,et al.Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation[J].Oncogenesis,2016,5:e198.
55 Koppe C,Reisinger F,Wehr K,et al.An NF-kappaB-and IKK-Independent function of NEMO prevents hepatocarcinogenesis by suppressing compensatory liver regeneration[J].Cancers(Basel),2019,11(7):999.

[1]	PANG Chunhua, LI Fanrong, TANG Rubing, QIN Lei, ZHAO Xinhua, TANG Juan, YOU Xuemei. Association between preoperative fatigue status and postoperative quality of life in patients with advanced hepatocellular carcinoma:a prospective cohort study [J]. Journal of Practical Oncology, 2022, 36(2): 127-132.
[2]	WANG Zongwen, LI Xiaodong, ZHU Qiankun, ZENG Shicong, ZHAI Bo. KIF14 in the mechanism of acquired drug resistance in hepatocellular carcinoma SMCC-7721 cells [J]. Journal of Practical Oncology, 2022, 36(1): 14-19.
[3]	DONG Lina, LIANG Tian, ZHANG Xian, ZHANG Guangmei. Research progress on tropism of ovarian cancer to fat-rich omentum organs [J]. Journal of Practical Oncology, 2022, 36(1): 54-58.
[4]	MU Guannan, MA Qiang. The role of NK cell polarization in endometrial cancer [J]. Journal of Practical Oncology, 2021, 35(6): 534-537.
[5]	LIU Fei, SUI Hong. Research progress in molecular classification of liver cancer based on tumor immunological microenvironment [J]. Journal of Practical Oncology, 2021, 35(6): 557-561.
[6]	JI Lei, JI Daolin, BAO Dongdong, TAN Gang. The latest research progress of long non-coding RNA in sorafenib resistance of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2021, 35(6): 562-567.
[7]	ZHAO Haoran, LI Man, ZHANG Yubao. Research progress of hepatocellular carcinoma-related RNA binding protein [J]. Journal of Practical Oncology, 2021, 35(6): 576-579.
[8]	LONG Yuanhui, CHEN Xuesong. Research progress on the effect of psychological stress on immune cells in tumor microenvironment [J]. Journal of Practical Oncology, 2021, 35(5): 436-440.
[9]	HE Ling, YAO Kecheng. Glycosylphosphatidylinositol transamidase and hepatocellular carcinoma [J]. Journal of Practical Oncology, 2021, 35(5): 458-461.
[10]	ZHOU Jian,CHEN Xuejian,WANG Wei,LI Ning,SUN Zhenyu,XU Lishan. The effect of silencing PRMT5 gene in biological behavior of human hepatocellular carcinoma cells [J]. Journal of Practical Oncology, 2020, 34(3): 208-213.
[11]	ZHANG Congyi, CUI Yifeng, LI Baobao, LIU Lianxin. Expression of cell division cycle 7 protein in hepatocellular carcinoma tissues and its effect on proliferation and invasion of hepatocellular carcinoma cells [J]. Journal of Practical Oncology, 2020, 34(2): 150-155.
[12]	ZHANG Huiting, LOU Ge. Research progress in 3D cell culture model of ovarian cancer tumor microenvironment [J]. Journal of Practical Oncology, 2019, 33(6): 557-560.
[13]	CHEN Ziyin, BAI Yanchun, CAO Yangsen, LI Jian, XU Lili, ZHAO Qiushuang, WANG Yang. Dosimetry advantage of respiratory gating in the treatment of hepatocellular carcinoma with large segmentation [J]. Journal of Practical Oncology, 2019, 33(6): 536-539.
[14]	QU Yanfei, LIU Chao, WANG Bojun, FANG Lin, ZHANG Yanqiao. Expression of CSN6 gene in hepatocellular carcinoma tissues and its clinical significance [J]. Journal of Practical Oncology, 2019, 33(4): 328-333.
[15]	HE Wei, MU Qiming, WANG Gang, WAN Bo, LIAO Bo, YANG Juan. Expression of TACC3 and p53 protein in primary liver cancer and its clinical significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 420-425.

The role of liver fibroblasts in the occurrence and development of hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments